Research
Hormonal
Pharmacologic management using GLP-1 receptor agonists (specifically liraglutide), topiramate, and phentermine/topiramate is effective for treating weight regain or weight loss plateaus following bariatric surgery.
If you are regaining weight after bariatric surgery, ask your provider about GLP-1 agonists (like liraglutide) or topiramate-based therapies. Current observational data supports their use for weight optimization in this specific population.
ModerateSupportsMEDIUM confidence
Observational studies in the post-bariatric surgery population consistently demonstrate the benefit of medical weight management after bariatric surgery, with most evidence highlighting liraglutide, topiramate, and phentermine/topiramate.
Why this rating
Evidence is primarily observational and retrospective; no large-scale RCTs for newer agents like semaglutide in this population are reported.
Source
Pharmacologic management of weight regain following bariatric surgery
Eugene Lucas et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2022.1043595
narrative_reviewCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Initiating anti-obesity medications (AOMs) at the weight loss plateau (WLP) is more effective for achieving additional weight loss than waiting until significant weight regain occurs.Moderate
- Newer GLP-1/GIP receptor agonists (semaglutide, tirzepatide) are expected to provide superior post-operative weight loss compared to prior GLP-1 RAs, despite a lack of specific post-surgical clinical trials.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →